{
    "clinical_study": {
        "@rank": "87319", 
        "arm_group": {
            "arm_group_label": "Pts with Hodgkin Lymphoma", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out whether BV with AVD chemotherapy and radiation is a\n      safe and effective treatment. It is hoped that this treatment will improve the ability to\n      cure more patients with HL."
        }, 
        "brief_title": "Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic diagnosis of classical, CD30 positive Hodgkin lymphoma confirmed at\n             enrolling institution\n\n          -  FDG-avid disease by FDG-PET/CT and measurable disease of at least 1.5 cm by CT\n\n          -  Ann Arbor Stage I or II disease\n\n          -  At least one of the following unfavorable risk factors as defined by GHSG: bulky\n             mediastinal mass (\u2265one-third maximum transverse thoracic diameter on\n             Posterior-Anterior/Lateral Chest X-ray or \u226510cm by CT imaging in axial plane), ESR \u2265\n             50mm/h or ESR \u226530 mm/h in patients with \"B\" symptoms, extranodal involvement, or 3 or\n             more involved lymph node sites.\n\n          -  Females of childbearing age must be on an acceptable form of birth control per\n             institutional standards\n\n          -  Age between 18 and 60\n\n        Exclusion Criteria:\n\n          -  Cardiac ejection fraction \u2264 50%\n\n          -  Hemoglobin-adjusted diffusing capacity for carbon monoxide < 60%\n\n          -  ANC\u22641000/\u03bcl and Platelets\u226475,000/\u03bcl\n\n          -  Total bilirubin \u2265 2.0 mg/dl in the absence of a history of Gilbert's disease\n\n          -  Known pregnancy or breast-feeding\n\n          -  Medical illness unrelated to Hodgkin Lymphoma, which, in the opinion of the attending\n             physician and/or MSKCC principal investigator, makes participation in this study\n             inappropriate.\n\n          -  Peripheral neuropathy > grade 1\n\n          -  Patients receiving treatment with systemic steroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868451", 
            "org_study_id": "13-034"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pts with Hodgkin Lymphoma", 
                "intervention_name": "Brentuximab vedotin (SGN-35)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pts with Hodgkin Lymphoma", 
                "intervention_name": "Doxorubicin HCL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pts with Hodgkin Lymphoma", 
                "intervention_name": "Vinblastine Sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pts with Hodgkin Lymphoma", 
                "intervention_name": "Dacarbazine", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Pts with Hodgkin Lymphoma", 
                "intervention_name": "Involved-Site Radiation Therapy (ISRT)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Pts with Hodgkin Lymphoma", 
                "intervention_name": "Interim PET", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dacarbazine", 
                "Doxorubicin", 
                "Vinblastine", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "DACARBAZINE", 
            "DOXORUBICIN/ADRIAMYCIN", 
            "SGN-35 (BRENTUXIMAB VEDOTIN)", 
            "VINBLASTINE", 
            "Involved-site radiation therapy (ISRT)", 
            "Early stage", 
            "13-034"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Craig Moskowitz, MD", 
                    "phone": "212-639-2696"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07920"
                    }, 
                    "name": "Memorial Sloan-Kettering at Basking Ridge"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Craig Moskowitz, MD", 
                    "phone": "212-639-2696"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Craig Moskowitz, MD", 
                    "phone": "212-639-2696"
                }, 
                "contact_backup": {
                    "last_name": "Joachim Yahalom, MD", 
                    "phone": "212-639-5999"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Craig Moskowitz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Carla Casulo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "University of Rochester Medical Center"
                }, 
                "investigator": {
                    "last_name": "Carla Casulo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Craig Moskowitz, MD", 
                    "phone": "212-639-2696"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memorial Sloan-Kettering at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Craig Moskowitz, MD", 
                    "phone": "212-639-2696"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma", 
        "overall_contact": {
            "last_name": "Craig Moskowitz, MD", 
            "phone": "212-639-2696"
        }, 
        "overall_contact_backup": {
            "last_name": "Joachim Yahalom, MD", 
            "phone": "212-639-5999"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Craig Moskowitz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "specifically non-infectious pneumonitis The definition of unacceptable pulmonary toxicity will be defined as the development of grade 2 or higher pneumonitis as defined by Common Terminology Criteria for Adverse Events (CTCAE version 4).", 
            "measure": "development of significant pulmonary toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868451"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression free survival (PFS) will be calculated from the time of initiation of brentuximab vedotin.", 
                "measure": "progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "(i.e. correlation with progression free survival) of interim fluorodeoxyglucose-positron emission tomography (PET) in this patient population measured by visual analysis and semi-quantitative analysis.", 
                "measure": "Evaluate the prognostic significance", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "using NanoString technology", 
                "measure": "Evaluate the prognostic significance of gene-expression based predictor", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "by quantitative PCR,", 
                "measure": "Evaluate the prognostic significance of gene-expression of plasma Epstein Barr virus DNA (EBV-DNA)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Seattle Genetics, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "University of Rochester", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}